Related Experiment Video
Updated: Jul 20, 2026
Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo
Published on: March 26, 2019
Liver X receptor activation decreases the severity of experimental autoimmune encephalomyelitis
Claudia Hindinger1, David R Hinton, Stefanie J Kirwin
1Department of Neurology, University of Southern California, Keck School of Medicine, Los Angeles, California, USA.
Abstract:
Agonists of liver X receptors (LXR), members of the nuclear hormone receptor superfamily, alter secretion of proinflammatory cytokines, suggesting potential antiinflammatory effects. A synthetic LXR agonist inhibited T-cell proliferation and cytokine release in a dose-dependent manner. Treatment of mice during induction of experimental autoimmune encephalomyelitis reduced clinical symptoms, central nervous system cellular inflammation, and major histocompatibility class II expression on microglia, as well as demyelination. In contrast to in vitro analysis, no reductions in peripheral neuroantigen specific T-cell responses were detected in comparing ligand and vehicle treated mice. These data suggest that LXR agonists play an important protective role in the regulation of T-cell-mediated inflammatory disease of the central nervous system.
Insights
Liver X receptor (LXR) agonists show anti-inflammatory effects by inhibiting T-cell responses. These compounds protect against T-cell-mediated central nervous system inflammatory diseases like experimental autoimmune encephalomyelitis.
Area of Science:
- Immunology
- Neuroscience
- Pharmacology
Background:
- Liver X receptors (LXR) are nuclear receptors involved in regulating lipid metabolism and inflammation.
- Altered secretion of proinflammatory cytokines by LXR agonists suggests potential anti-inflammatory roles.
Purpose of the Study:
- To investigate the therapeutic potential of LXR agonists in T-cell-mediated central nervous system (CNS) inflammatory diseases.
- To evaluate the effects of a synthetic LXR agonist on T-cell proliferation, cytokine release, and experimental autoimmune encephalomyelitis (EAE) in vivo.
Main Methods:
- In vitro assessment of LXR agonist effects on T-cell proliferation and cytokine release.
- In vivo treatment of mice during EAE induction with a synthetic LXR agonist.
- Evaluation of clinical symptoms, CNS inflammation, microglial activation (MHC class II expression), and demyelination in treated mice.
Main Results:
- A synthetic LXR agonist dose-dependently inhibited T-cell proliferation and cytokine release in vitro.
- LXR agonist treatment significantly reduced clinical symptoms, CNS inflammation, and demyelination in EAE mice.
- No reduction in peripheral neuroantigen-specific T-cell responses was observed in vivo.
Conclusions:
- LXR agonists demonstrate significant protective effects in T-cell-mediated CNS inflammatory diseases.
- The anti-inflammatory mechanisms of LXR agonists in the CNS warrant further investigation.
- LXR agonists represent a potential therapeutic strategy for neuroinflammatory conditions.
